C2 Pharma doubles down on supplies of digoxin API

Luxembourg-based C2 Pharma, which already has a manufacturing agreement with Laurus Labs in India, has now bought a new supply of digoxin API. (Lauras Labs)

C2 Pharma, which concentrates on hard-to-make ingredients, has picked up a new supply of digoxin. The deal will give it two supplies of API for making the sometimes-difficult-to-get drug.

The Luxembourg-based company has acquired the digoxin API product portfolio of Polish company Nobilus. The company said that through the agreement, C2 Pharma is the product owner and Nobilus is a manufacturing partner and releasing entity for the API. Terms of the deal were not disclosed.

“While this type of investment is unprecedented for such a niche product, we believe that it is the most responsible path to secure a quality, continuous supply of this complex and essential API,” C2 Pharma CEO Andrew Badrot said in a statement.  

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

He pointed out that because of tighter regulatory oversight and the impurity and supply chain issues of some makers, supplies of digoxin APIs have been difficult for drugmakers to get since 2014.

C2 Pharma already has a long-term supply agreement and partnership with Indian API maker Laurus Labs. Last fall, the two validated the manufacturing process for two APIs, digoxin and digoxin micron, at a dedicated manufacturing facility at Laurus Labs' site in Vizag, India. In 2016, C2 invested about $10 million to build the 1,800-square-meter facility. It says the annual production of that facility equals the entire global demand for digoxin.

The company says that with the parallel manufacturing by Nobilus and Laurus, C2 Pharma can ensure redundancy and constant supply.

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.